**Background**
Hypertension is a chronic medical condition characterized by persistently elevated blood pressure in the arteries, which significantly increases the risk of cardiovascular diseases, stroke, and renal failure. Managing blood pressure often involves targeting the sympathetic nervous system to reduce peripheral vascular resistance and cardiac output. Among the various therapeutic strategies, centrally acting agents that modulate adrenergic receptors in the brain provide a potent means of lowering blood pressure. The $\alpha_2$-adrenergic receptor, in particular, plays a critical role in regulating the release of norepinephrine and modulating sympathetic outflow. In this context, we will introduce a potent antihypertensive agent – Methyldopa.
**Definition**
Methyldopa (L-(-)-$\alpha$-Methyldopa hydrate) is an $\alpha$-adrenergic agonist that selectively targets $\alpha_2$-adrenergic receptors. According to the Methyldopa technical information, it serves as a proagent that is metabolized into $\alpha$-methylepinephrine within the central nervous system to exert its pharmacological effects.
**In Vivo Studies**
The Methyldopa biological activity has been explored in various physiological models to understand its systemic impact. In vivo studies utilizing 60-day-old male rats demonstrated that Methyldopa (200 mg/kg; i.p.) can effectively modulate metabolic responses. Specifically, the administration of this compound decreased the hyperglycemic response during the first 2 hours following treatment with Dieldrin. Detailed results indicated that Methyldopa in vivo administration reduced the plasma concentration of glucose in Dieldrin-exposed rats by 24% within the 30 minutes following its delivery. These findings suggest that beyond its primary role in blood pressure regulation, the compound may influence glucose homeostasis in specific toxicological models. In conclusion, Methyldopa is a selective $\alpha_2$-adrenergic agonist with potent antihypertensive properties and metabolic regulatory effects.
Keywords
Methyldopa, 41372-08-1, L-(-)-α-Methyldopa, MK-351, MK351, MK 351, Adrenergic Receptor, Endogenous Metabolite, Beta Receptor, antihyoertensive, prodrug, metabolized, hyperglycemic, response, Inhibitor, inhibitor, inhibit
References
[1] Sweet CS. New centrally acting antihypertensive drugs related to methyldopa and clonidine. Hypertension. 1984;6(5 Pt 2):II51-II56.
[2] Fox GR, et al. The effects of phenobarbital, atropine, L-alpha-methyldopa, and DL-propranolol on dieldrin-induced hyperglycemia in the adult rat. Toxicol Appl Pharmacol. 1985;78(3):342-350.